Your session is about to expire
← Back to Search
Tranexamic Acid for Major Non-Cardiac Surgery (TRACTION Trial)
TRACTION Trial Summary
This trial looks at whether using Tranexamic acid can help reduce the amount of blood transfusions needed during major non-cardiac surgery.
TRACTION Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTRACTION Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TRACTION Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I received TXA for a trauma surgery within the last 3 hours.I have had surgery for a bone injury or amputation in my hip, pelvis, femur, shoulder, or leg.I have had surgery on my lung.I am 18 or older and will have a major surgery that is not heart-related.I have had major abdominal surgery.I have had a hysterectomy.I have had plastic surgery for large tumor removal, burns, or wound cleaning.My upcoming surgery has a high risk of needing a blood transfusion.I have had surgery on the large arteries near my heart.I have had surgery that might qualify me for this trial.I have had major spine surgery.I am on blood thinners for a clotting disorder before joining the study.I am undergoing cardiac surgery or hip/knee replacement where TXA is a standard treatment.I have had surgery on my kidneys, bladder, prostate, or pelvic area.My surgery is expected to last 3+ hours or has a high risk of needing a blood transfusion.I had surgery with tissue moved from one part of my body to another.I have had surgery to remove part of my tongue, jaw, or voice box.
- Group 1: Tranexamic acid (TXAl Arm
- Group 2: Placebo Arm
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what magnitude is the participant population involved in this research?
"Affirmative. The clinical trial portal indicates that this medical investigation, initially posted on February 16th 2022, is currently recruiting participants. Approximately 8320 individuals must be sourced from 3 distinct healthcare sites."
For what maladies is Tranexamic acid (TXAl Arm utilized?
"Hyperfibrinolysis is commonly treated with Tranexamic acid (TXAl Arm, which can also be used to help manage hemophilia, bleeding disorders and the post-operative blood loss from tooth extractions."
Are there any potential adverse effects of utilizing Tranexamic acid (TXA) for patients?
"Leveraging clinical data and safety trials, our assessment at Power gave Tranexamic acid (TXAl Arm) a score of 3 as it is approved for medical use."
Has there been any previous research regarding the efficacy of Tranexamic acid (TXA) for treatment?
"Tranexamic acid was initially investigated in 2010 by the First Affiliated Hospital of Guangzhou TCM University and there have since been 216 completed trials. In 2021, 61 studies are currently ongoing, with much of this research taking place in Winnipeg, Manitoba."
Are there any opportunities to enroll in this experiment at present?
"Indeed, according to the clinicaltrials.gov website, this research trial is actively recruiting subjects. It was first posted on February 16th 2022 and underwent its most recent update on April 5th of that year. The study requires 8320 participants across 3 distinct sites."
What outcomes is this experiment aiming to produce?
"The primary goal of this experiment is to determine the proportion of RBC transfusions over a 3 month window. Secondary objectives include establishing how many units were transfused, if any arterial/venous thrombotic events occurred, and quantifying the days at home up until day 30 (DAH30)."
Share this study with friends
Copy Link
Messenger